show me the money

Report finds Houston is 3rd fastest growing tech ecosystem

Houston Exponential released a new report on venture capital activity in the Bayou City. Sky Noir Photography by Bill Dickinson/Getty Images

In the startup world, small funding deals are a big deal in Houston.

A new Houston Exponential analysis based on data from PitchBook shows early-stage and angel rounds accounted for 151 venture capital deals under $5 million last year. Nearly two-thirds of those VC deals were less than $1 million.

Thanks to that robust activity, Houston now ranks as the third-fastest-growing tech ecosystem for early-stage companies in the country, according to the analysis.

Meanwhile, last year’s overall VC deal count exceeded 200 for the first time, “a harbinger of future growth potential as new company creation continues to explode,” the analysis says.

Texas Medical Center is contributing to that explosion. It recently raised the size of its TMC Venture Fund to $50 million. TMC says the fund now will be able to back a wider range of early-stage startups.

“When we launched the TMC Venture Fund, our goal was to drive collaboration and entrepreneurship, and establish Texas as a life science hub,” William McKeon, president and CEO of TMC, says in a news release. “Our initial investment was extremely successful, and this influx of capital creates a unique opportunity for TMC to invest in companies in the earliest stages of commercialization, further bolstering Houston’s thriving life science community.”

Although Houston’s average early-stage deal size of $18 million remains shy of the national average of $21 million, that still represents a 68 percent growth rate since 2019, according to the analysis from Houston Exponential, an entrepreneurship hub. Compared with the national growth rate of 23 percent, “this demonstrates the broader expansion and maturities within the Houston ecosystem,” the analysis says.

The size of deals at the Series A and Series B levels also is on the rise. According to the analysis, the median Series A round in Houston grew from less than $3.2 million in 2020 to more than $10 million in 2021. The size of Series B rounds rose 35 percent, from a median of $13.6 million in 2020 to $21 million in 2021.

While those numbers are impressive, mega-deals stole the spotlight in 2021. Six Houston companies raised at least $100 million last year, with three of those deals surpassing $300 million. Collectively, Axiom Space, Cart.com (now based in Austin), HighRadius, Lancium, Solugen, and Vyripharm Biopharmaceuticals raised $1.3 billion last year.

Last year’s mega-deals brought the number of Houston unicorns, including Cart.com, to five. Unicorns are startups valued at $1 billion or more. In Houston, the newest members of that club are Solugen, with a $357 million Series C round in 2021, and Cart.com, with a $240 million Series B1 round last year.

“That VC-backed companies were able to generate such enormous value in 2021 during a time characterized by great uncertainty and extraordinary circumstances highlights the continued importance of VC-backed companies to the resilience of Houston’s economy,” says Serafina Lalany, executive director of Houston Exponential.

Trending News

Building Houston

 
 

Five companies have been selected for a brand new accelerator program in Houston. Image via Getty Images

A Houston medical technology organization has announced the inaugural cohort of a new early-stage accelerator.

M1 MedTech, launched this year by Houston-based Proxima Clinical Research, announced its Fall 2022 cohort.

“This initial cohort launches M1 MedTech with an interactive 14-week agenda covering the basics every emerging MedTech business needs to progress from a startup to an established solution in their market,” says Sean Bittner, director of programs at M1 MedTech, in a news release.

The accelerator will equip early-stage startups with storytelling, business plan support, investor connections, FDA guidance, research, and more through one-on-one consultations, workships, and in-kind services.

The first cohort includes five startups, per the release from the company:

  1. Linovasc. Providing a long overdue major update to balloon angioplasty devices in over 50 years, the Linovasc solution offers a safer branch occlusion and aortic stent dilatation using a toroidal balloon that expands the aorta uniformly without the ischemia caused by current treatments. The company is founded by Bruce Addis.
  2. Grapheton. Founded by Sam Kassegne and Bao Nguyen, Grapheton's patented carbon materials work with electrically active devices to improve the longevity and outcome of bioelectric implants in the body. Terry Lingren serves as the CEO of the startup.
    • Rhythio Medical. Founded by Kunal Shah and Savannah Esteve, Rhythio is the first preventative approach to heart arrhythmias.The chief medical officer is Dr. Mehdi Razavi.
      • PONS Technology. An AI cognitive functioning ultrasound device attempting to change the way ultrasound is done, PONS is founded by CEO: Soner Haci and CTO: Ilker Hacihaliloglu.
        • Vivifi Medical. Founded by CEO Tushar Sharma, Vivifi is the first suture-less laparoscopic technology that connects vessels to improve male infertility and benign prostatic hyperplasia. The company's senior R&D engineer is Frida Montoya.

          The program includes support from sponsors and experts from: Proxima Clinical Research, Greenlight Guru, Medrio, Galen Data, Merge Medical Device Studio, Venn Negotiation, Engagement PR & Marketing, Aleberry Creative, and others.

          “This is an amazing opportunity for emerging founders to learn the progression of pipelining their ideas through the FDA and absorb the critical strategies for success early in their business development,” says Isabella Schmitt, principal at M1 MedTech and director of regulatory affairs at Proxima CRO, in the release.

          Trending News